AccessibilityHelpAbout Us
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(OTC) HKMPF

Market Cap$4.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+210%
5 Year-27%
1 Year-0%
1 Month-5%
$21.10
+0.00%
+0.00Today
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 21.102026-09-23
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.9%USD 22.192026-09-15
1 month-4.9%USD 22.192026-08-24
3 month+11.28%USD 18.962026-06-18
Year to date+5.44%USD 20.012025-12-29
1 year-0.04%USD 21.112025-09-23
3 year-12.62%USD 24.152023-09-19
5 year-27.36%USD 29.052021-09-23
Since inception+209.68%USD 6.812007-06-28

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.62B

Net Income (TTM)

$755.76M

EPS (TTM)

$1.77

P/E Ratio

11.73

Dividend

$0.86

Beta (Volatility)

0.28 (Low)

Price

$21.10

Volume

6

Open

$21.11

Previous Close

$21.10

Daily Range

$21.10 - $21.11

52-Week Range

$16.34 - $25.34

Estimated Earnings Date

Feb 25, 2027

HKMPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications. The company operates through three core segments: Injectables, Generics, and Branded products, addressing diverse medical needs across various therapeutic areas.

Products and Services
  • Injectables: Generic injectable medications primarily for hospitals
  • Generics: Oral and non-injectable generic drugs for the retail market
  • Branded: Proprietary generics and in-licensed pharmaceuticals for consumers
Growth Outlook
  • Revenue of $1.7 billion in Q2 2026, showing strong market demand
  • Net income of $219.8 million in Q2 2026, reflecting effective cost management
  • Expansion into new markets, enhancing global reach and sales potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of $6.7 billion, indicating consistent growth
  • Net profit margin of 11.3% TTM, showcasing operational efficiency
  • Dividend yield of 4.14% TTM, appealing for income-focused investors
Hikma Pharmaceuticals PLC has established itself as a significant player in the pharmaceutical industry, with a diverse product portfolio that meets various healthcare needs. The company's focus on injectables, generics, and branded products allows it to cater to a wide range of markets, enhancing its competitive edge. Recent financial performance indicates robust growth, with a notable increase in revenue and net income, reflecting effective management strategies and market demand. The company's commitment to expanding its global footprint further positions it for future success, making it an intriguing option for potential investors.
AI Generated • Sep 11, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1H 6AZ, GB

HKMPF Financials

Key Financial Metrics (TTM)

Gross Margin

40.88%

Operating Margin

19.41%

Net Income Margin

11.31%

Return on Equity

15.05%

Return on Capital

13.82%

Return on Assets

6.59%

Earnings Yield

8.53%

Dividend Yield

4.08%

Payout Ratio

46.65%

Stock Overview

Market Cap

$4.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

206.97M

Volume

6

Avg. Volume

596.234

Financials (TTM)

Gross Profit

$2.78B

Operating Income

$1.18B

EBITDA

$1.65B

Operating Cash Flow

$922.78M

Capital Expenditure

-$411.78M

Free Cash Flow

$511.00M

Cash & ST Invst.

$288.66M

Total Debt

$1.95B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,517,000,000-1.4%
20232023-12-31USD 2,875,000,00014.2%
20242024-12-31USD 3,127,000,0008.8%
20252025-12-31USD 3,349,000,0007.1%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-312.6%
Q22026-06-300.1%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.84-53.8%
20232023-12-31USD 0.852.2%
20242024-12-31USD 1.6188.0%
20252025-12-31USD 1.8112.4%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-40.6%
Q22025-06-3078.3%
Q42025-12-31-30.8%
Q22026-06-3036.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.70B

+8.5%

Gross Profit

$717.47M

-5.1%

Gross Margin

42.13%

N/A

Market Cap

$4.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$464.58K

N/A

Employees

9,400

N/A

Net Income

$219.77M

-2.8%

EBITDA

$475.03M

-4.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$288.66M

+11.0%

Total Debt

$1.95B

+53.2%

Accounts Receivable

$1.12B

+19.5%

Inventory

$1.17B

+25.5%

Long Term Debt

$1.75B

+65.0%

Short Term Debt

$203.76M

-5.2%

Return on Assets

6.59%

N/A

Return on Invested Capital

14.83%

N/A

Free Cash Flow

$46.32M

-64.1%

Operating Cash Flow

$166.55M

-15.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNPUFSumitomo Pharma Co., Ltd.
$9.79+0.00%
FLMNFFielmann AG
$42.50+0.00%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
OPHLYOno Pharmaceutical Co., Ltd.
$5.14-2.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.35+83.85%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.63-0.09%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$146.33+0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$34.18+0.12%

Questions About HKMPF

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at $21.10 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between $16.34 and $25.34.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.60B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $328.00M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 4.08%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services